home icon

right icon

Stocks

right icon

KILITCH

KILITCH

Pharmaceuticals & Drugs

162.4

0.00 (0.00%)

stock change
Market Cap253 CrEPS8.0High163.4
Stock P/E20.3Net Profit Margin6.3Low158.5
home icon
The current prices are delayed, login to your account to see live prices.
LOGIN
explain

Performance

Today’s Low

Today’s High

158.5

163.4

52W Low

52W High

145

275.1

Open Price162.4Volume1
Prev. Close162.4
explain

Fundamentals

explain
Market Cap253 CrROE4.7%
P/E Ratio(TTM)20.3EPS(TTM)5.3
P/B Ratio1.4Dividend Yield0.0%
Industry P/E65.5Book Value119.6
Face Value10.0
explain

About the Company

Kilitch Drugs is a pharmaceutical company, its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms. With nearly two decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.

Kilitch is one of the largest manufacturers of antibacterial parenteral formulations. It is also one of the largest producers of sterile liquid formulations in small volumes in India. Kilitch also boasts of 25 years of quality contract manufacturing service to reputed national and multinational pharmaceutical companies. its sound knowledge about the industry has resulted in the growth of the organizations along with them as a leading contract manufacturing company in the country.

Keeping pace with the increasing demand of its clients for contract manufacturing, Kilitch has added 2 dedicated blocks and is in the process of adding another 3 dedicated fully USFDA / UKMHRA compliant manufacturing facility in Paonta Sahib (North India). All its plants are approved by the local as well as World Health Organization (WHO) for GMP standards. Kilitch has 3 manufacturing facilities spread across India.

Kilitch has over 25 years of experience in product development and manufacturing. It offers a wide spectrum of contract services, providing reliable supply, scientific expertise and bottom line results to meet the development, clinical and commercial outsourcing needs. Kilitch has been engaged in successful tie-ups with over 20 leading pharmaceutical companies -- Ranbaxy Laboratories Limited, Sandoz India Limited, Zydus Cadila, Nicholas Piramal India Limited, USV Limited, Merck Limited to name a few.

In 2010 the company listed its Equity Shares at NSE.

DCGI Approval-- The company has received the DCGI approvals for Ceftriaxone+Tazobactam, Ceftriaxone+Salbactam,Cefipime +Tazobactam and awaiting for approval for the following products, Rabeprazole, Ceftazidime+Tazobactam, Cefoperazone+Tazobactam

Product range of the company includes- Carbapenems, Cephalosporins, Beta - Lactam Antibiotics, Steroids & Hormones, Gastrology, Gastrology, NSAIDs, Anti Malarials

Kilitch has signed an agreement with a US-based pharmaceutical company for manufacturing of its generic molecules for the period of 2 year which started in mid 2008 and would like to expand their business thereon.

Clientele: Sandoz, Ranbaxy, Emcure, Nicholas, Ajanta pharma, Zuventas, Zydus Cadilla, USV, Flamingo Pharma and many others.

Parent OrganisationKilitch Drugs (India) Ltd.Managing DirectorMukund P Mehta
Founded1992NSE SymbolKILITCH
explain

Financials

All values are in Rs Cr

explain

Shareholding Pattern

explain

Peer Comparison

Company52 WeekMarket PriceP/E Ratio
SEE MORE
explain

Recently Viewed

No Recently Viewed Stocks
explain

Frequently asked questions

You can buy the shares of Kilitch Drugs using the Trinkerr Website or by downloading the Trinkerr app from Android and Apptore.